Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Van Hilten, J J ^a   Ramaker, C C ^b   Stowe, R L ^b   Ives, N J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Antiparkinson agents *therapeutic use ; Bromocriptine *therapeutic use ; Combined modality therapy; Human; Levodopa *therapeutic use ; Parkinson disease *drug therapy ; Randomized controlled trials as topic

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; LEVODOPA; PLACEBO;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DATA ANALYSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HALLUCINATION; HUMAN; IDIOPATHIC DISEASE; INFORMATION PROCESSING; MONOTHERAPY; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STANDING; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 44949228357     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003634.pub2     Document Type: Review

References (52)

1. Alarcón 1998 {published and unpublished data} Alarcón F, Cevallos N, Lees AJ. Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent latemotor complications?. European Journal of Neurology 1998;5:255-63.
2. Bakheit 1990 {published data only} Bakheit AM, Henderson LM, Moore AP, Simpson JA, Thomas M. Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease. Interim results. European Neurology 1990;30:108-11.
3. Giménez 1997 {published and unpublished data} Giménez-Roldan S, Tolosa E, Burguera JA, Chacon J, Liano H, Forcadell F. Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clinical Neuropharmacology 1997;20(1):67-76. [MEDLINE: UI: 97189317].
4. Herskovits 1988 {published data only} Herskovits E, Yorio A, Leston J. Long term bromocriptine treatment in de novo parkinsonian patients. Medicina (B Aires) 1988;48(4):345-50. [MEDLINE: UI: 89343576].
5. Olsson 1990 {published data only} Olsson JE, Rascol A, Korten JJ, Dupont E, Gauthier G. Early treatment with a combination of bromocriptine and levodopa compared with levodopa monotherapy in the treatment of Parkinson's disease. Current Therapeutic Research 1989;46(5): 1002-14.
6. *Olsson JE and The European Multicentric Trial Group. Bromocriptine and levodopa in early combination in Parkinson's Disease; first results of the Collaborative EuropeanMulticentric Trial. Advances in neurology. Vol. 53: Parkinson's disease: anatomy, pathology, and therapy. Raven Press, 1990.
7. Przuntek 1996 {published and unpublished data} Przuntek H, Welzel D, Gerlach M, Blumner E, Danielczyk W, Kaiser HJ, et al.Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associatedmotor side effects. Long-term results of the PRADO study. Journal of Neural Transmission General Section 1996;103:699-715. [MEDLINE: UI - 96433953].
8. Weiner 1993 {published and unpublished data} Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon RN, Cornelius L, et al.Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43(1):21-7. [MEDLINE: UI: 93140995].
9. Fischer 1984 *Fischer PA, Przuntek H, Majer M, Wezel D. Kombinationsbehandlung fruher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Deutsche Medizinische Wochenschrift 1984;109:1279- 83. [MEDLINE: UI: 84285059].
10. Kowa 1997 Kowa H, Kanazawa I, Goto I, Kuno S, Mizuno Y, Ogawa N, et al.Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease. European Neurology 1997;38(Suppl 1):S23-8.
11. Kuno 1993 Kuno S. Progress note on Japanese multicenter bromocriptine monotherapy. European Neurology 1993;33(Suppl 1):3-5.
12. Montastruc 1990 *Montastruc JL, Rascol O, Rascol A. Comparison of bromocriptine and levodopa as first line treatment Parkinson's disease: results of a 3-year prospective randomized study. Revue Neurologique 1990;146:144-7.
13. Montastruc 1994 Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52:773-5.
14. Montastruc JL, Rascol O, Rascol A. Bromocriptine versus levodopa in the early treatment of Parkinson's disease. 1st results after 2 years. Therapie 1988;14:576-80.
15. *Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. Journal Neurology, Neurosurgery, and Psychiatry 1994;57:1034-8. [MEDLINE: UI: 94376091].
16. Nakanishi 1988 Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, et al.A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan. European Neurology 1988;28(Suppl 1):S3-8.
17. Nakanishi 1989 Nakanishi T, Iwata M, Goto I, Kanazawa I, Kowa H, Mannen T, et al.Second interim report of the nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. European Neurology 1989;29(Suppl 1):S3-8. [MEDLINE: 196].
18. Nakanishi 1990 Nakanishi T, Kanazawa I, Goto I, Iwata M, Kowa H, Mannen T, et al.Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. European Neurology 1990;30(Suppl 1):S3-8.
19. Nakanishi 1991 Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, et al.A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. European Neurology 1991;31(Suppl 1):S3-16.
20. Nakanishi 1992 Nakanishi T, Iwata M, Goto I, Kanazawa I, Kowa H, Mannen T, et al.Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report. European Neurology 1992;32(Suppl 1):S9-22.
21. Ogawa 1997 *Ogawa N, Kanazawa I, Kowa H, Kuno S, Mizuno Y, Tashiro K, et al.Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up. European Neurology 1997;38(Suppl 2):S37-49.
22. Presthus 1977 *Presthus J. A double-blind study with BB-154 (bromocriptine) compared with placebo on patients with Parkinson's disease treated with levodopa. Proceeding of the 11th World Congress of Neurology; 1977; Sept 11-16; Amsterdam. Excerpta Medica, 1977.
23. Tashiro 1996 Tashiro K, Goto I, Kanazawa I, Kowa H, Kuno S, Mizuno Y, et al.Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease. European Neurology 1996;36(Suppl 1):S32-7.
24. Yanagisawa 1994 Yanagisawa N, Kanazawa I, Goto I, Kowa H, Kuno S, Mizuno Y, et al.Seven-year follow-up study of bromocriptine therapy for Parkinson's disease. European Neurology 1994;34(Suppl 3):S29-35.
25. Ahlskog 1996 Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified?. Mayo Clinic Proceedings 1996;71(7):659-70.
26. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al.Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. [MEDLINE: 652].
27. Bernheimer 1973 Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 1973;20(4):415-55. [MEDLINE: UI: 74081469].
28. Calne 1974 Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of parkinsonism with bromocriptine. Lancet 1974;2:1355-6.
29. Canter 1961 Canter GJ, de la Torre R, Mier M. A method of evaluating disability in patients with Parkinson's disease. Journal of Nervous and Mental Disease 1961;133:143-7.
30. Corrodi 1973 Corrodi H, Fuxe K, Hokfelt T, Lidbrink P, Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. Journal of Pharmacy and Pharmacology 1973;25(5):409-12.
31. England 1956 England AC, Schwab RS. Postoperative evaluation of selected patients with Parkinson's disease. Journal of the American Geriatric Society 1956;4:1219-32.
32. Factor 1993 Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Movement Disorders 1993;8(3):257-62.
33. Fahn 1987 Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: FahnS, GoldsteinM, MarsdenD, CalneDB editor(s). Recent developments in Parkinson's disesase. Vol. II, Florham Park, New Jersey: Macmillan, 1987:153-63.
34. Goetz 1990 Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(10:Suppl 3):S50-4.
35. Goldstein 1983 Goldstein M, Engel J, Lieberman A, Regev I, Bystritsky A, Mino S. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists. Journal of Neural Transmission Supplement 1983;18:257-63.
36. Hoehn 1981 Hoehn MM. Bromocriptine and its use in Parkinsonism. Journal of the American Geriatric Society 1981;29(6):251-8.
37. Hornykiewicz 1966 Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews 1966;18(2):925-64.
38. Lees 1989 Lees AJ. The on-off phenomenon. Journal of Neurology, Neurosurgery, and Psychiatry 1989;(Special suppl):29-37. [MEDLINE: 634].
39. Lieberman 1985 Lieberman AN, Goldstein M. Bromocriptine in Parkinson disease. Pharmacological Reviews 1985;37(2):217-7.
40. Marsden 1976 Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-6.
41. Marsden 1982 Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: MarsdenCD, FahnS editor (s). Movement Disorders. London: Butterworths Scientific, 1982:96-122.
42. Montastruc 1988 Montastruc JL, Rascol O, Rascol A. Bromocriptine versus levodopa in the early treatment of Parkinson's disease. 1st results after 2 years. Therapie 1988;14:576-80.
43. Montastruc 1989 Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52:773-5.
44. Ogawa 1998 Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 1998;51(2 Suppl 2):S13-20.
45. Ramaker 2000 Ramaker C, van de Beek WJ, Finken MJ, van Hilten BJ. The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: a systematic review. Movement Disorders 2000;15(1):56-64.
46. Ramaker 2004 Ramaker C, Hilten JJ van. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database of Systematic Reviews 2004, Issue 2.Art. No.: CD002258. DOI:10.1002/14651858.CD002258. pub2.
47. Schoppe 1974 Schoppe KJ. Das MLS-Gerät: Ein neuer Testapparat zur Messung feinmotorischer Leistungen. Diagnostica 1974;20:43-7.
48. Shaw 1980 Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Quarterly Journal of Medicine 1980;49(195):283-93.
49. van Hilten 2000 van Hilten JJ, Ramaker C, van de Beek WJT, Finken MJJ. Bromocriptine for levodopa-inducedmotor complications in Parkinson's disease (Cochrane Review). In: The Cochrane Library Issue 1, 2000. Oxford: Update Software.
50. Watts 1997 Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997;49(1 Suppl 1):S34-48.
51. Webster 1968 Webster DD. Critical analysis of the disability in Parkinson's disease. Modern Treatment 1968;5(2):257-82.
52. Yahr 1969 Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Archives of Neurology 1969;21 (4):343-54.